Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-26T04:37:57.421Z Has data issue: false hasContentIssue false

Carboplatin ototoxicity: an animal model

Published online by Cambridge University Press:  29 June 2007

Mark Wake*
Affiliation:
Department of Otolaryngology and Auditory Science Laboratory, Toronto.
Sachio Takeno
Affiliation:
Department of Otolaryngology and Auditory Science Laboratory, Toronto.
Danyl Ibrahim
Affiliation:
Department of Otolaryngology and Auditory Science Laboratory, Toronto.
Robert Harrison
Affiliation:
Department of Otolaryngology and Auditory Science Laboratory, Toronto.
Richard Mount
Affiliation:
Department of Otolaryngology and Auditory Science Laboratory, Toronto.
*
M. Wake, F.R.C.S., Department of Otolaryngology, Sunnybrook Health Science Centre, Suite #A208, 2075 Bayview Avenue, Toronto, Ontario M4N 3HT, Canada. Fax: (0101)416 480 6830.

Abstract

A new animal model of ototoxicity is presented using intravenous carboplatin in adult chinchillas. A range of physiological and morphological effects was produced using doses calculated from the recommended therapeutic range (200–400 mg/m2). Auditory thresholds to tone pips stimuli were monitored using brain stem evoked responses (ABR). Cochlear histopathology was studied by light microscopy (LM) and ultrstructural hair cell abnormalities investigated with scanning electronmicroscopy (SEM). Carboplatin in this animal model predominantly affected the inner hair cells. This may provide an important model for the study of selective loss of the main afferent input in the auditory system.

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Al-Sharraf, M., Metch, B., Krish, J., Ensley, J., Rinehart, J., Schuller, D., Coltman, C. (1987) Platinum analogues in recurrent and advanced head and neck cancer. Cancer Treatment Reports 71 (7–8): 723726.Google Scholar
Anzai, T., Asukimas, S., Snow, J. (1987) Ototoxicity of carboplatin and its transferability into inner ear-comparative study of carboplatin. Ear Research Japan 18: 122124Google Scholar
Calvert, A., Harland, S., Newell, D., Siddik, Z., Jones, A., McElivan, J., Raju, S., Whiltshaw, E., Smith, D., Baker, J., Peckham, M., Harrop, K. (1982) Early clinical studies with cis-diammine-1, 1-cyclobutane dicarboxylate platinum II. Cancer Chemotherapy and Pharmacology 9: 140147CrossRefGoogle ScholarPubMed
Castello, M., Clerico, A., Deb, G., Dominici, C, Fidani, P., Donfrancesco, A. (1990) High dose carboplatin in combination with etoposide for childhood brain tumours. American Journal of Pediatric Hematology/Oncology 12(3): 297300.CrossRefGoogle Scholar
Evans, W. K., Eisenhower, E., Hughes, P., Maroun, J., Ayoub, J., Shepard, E., Feld, R. (1988) VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer. British Journal of Cancer 58 (4): 464468CrossRefGoogle ScholarPubMed
Kennedy, I., Fitzharris, B., Colls, B., Atkinson, C. (1990) Carboplatin is ototoxic. Cancer Chemotherapy and Pharmacology 26 (3): 232234Google Scholar
Komune, S., Asukimas, S., Snow, J. (1981) Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum in the male rat. Cancer Chemotherapy Reports 55: 18Google Scholar
Leyvraz, S., Ohnuma, X., Lassus, M., Holland, J. (1985) Phase I study of carboplatin in patients with advanced cancer, intermittent intravenous bolus and 24 hour infusion. Journal of Clinical Oncology 3 (10), 13851392.Google Scholar
Myers, E., Welborn, J., Lewis, J., Flynn, N. (1989) Infusion carboplatin treatment for relapsed and refractory acute leukaemia. Journal of Clinical Oncology 7 (2): 173178CrossRefGoogle Scholar
Nichols, C, Truot, G., Williams, S., van Besien, K., Laehrer, P., Roth, B., Akard, L., Hoffman, R., Goulet, R., Wolff, S. (1989) Dose intensive chemotherapy in refractory germ cell cancer-a phase I/II trial of high dose carboplatin and etoposide with autologous bone marrow transplant. Journal of Clinical Oncology 7(7): 932939.CrossRefGoogle Scholar
Rosenberg, B., van Camp, L., Krigas, T. (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205: 698699CrossRefGoogle ScholarPubMed
Rosenberg, B., van Camp, L., Trosko, J., Mansow, J. (1969) Platinum compounds: a new class of potent antitumour agents. Nature 111: 385386CrossRefGoogle Scholar
Saito, T, Saito, H., Saito, K., Wakui, S., Manabe, Y., Tsuda, G. (1989) Ototoxicity of carboplatin in guinea pigs. Auris-Nasus-Larynx 16 (1): 1321Google Scholar
Schweitzer, V., Rarey, K., Dolon, D., Abrams, G., Litterst, C., Sheridan, C. (1986) Ototoxicity of cisplatin versus platinum analogues CBDCA (JM-8) and CHIP (JM-9). Otolaryngology—Head and Neck Surgery 94 (4): 458470CrossRefGoogle Scholar
Stadnick, S., Fleischman, R., Scheppi, U., Merrian, P. (1975) Cisdichlorodiammineplatinum II - hearing loss and other toxic effects in rhesus monkeys. Cancer Chemotherapy Reports 59: 467480Google Scholar
Van der Hulst, R., Dreschler, W., Urbanus, N. (1988) High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Annals of Otology, Rhinology and Laryngology 97: 133137Google Scholar
Van Hennik, M., van der Vijgh, W., Klein, I., Elferink, E., Vermorken, J., Winograd, B., Pinedo, H. (1987) Comparative pharmacokinetics of cisplatin and three analogues in mice and humans. Cancer Research 47: 62976301Google Scholar
Woloschuk, D., Pruemer, J., Cluxton, R. (1988) Carboplatin: a new cisplatin analog. Drug Intelligence and Clinical Pharmacy 22: 843849CrossRefGoogle ScholarPubMed
Wright, C, Shaeffer, S. (1982) Inner ear histopathology in patients treated with cisplatin. Laryngoscope 92: 14081413CrossRefGoogle Scholar